Interventions to decrease the risk of adverse cardiac events for patients receiving chemotherapy and serotonin (5-HT3) receptor antagonists: a systematic review
Tricco AC, Soobiah C, Hui W, Antony J, Struchkov V, Hutton B, Hemmelgarn B, Moher D, Straus SE. Interventions to decrease the risk of adverse cardiac events for patients receiving chemotherapy and serotonin (5-HT3) receptor antagonists: a systematic review. BMC Pharmacol Toxicol. 2015 Jan 26;16:1. doi: 10.1186/2050-6511-16-1.
[sidebar] Commissioned and Funded by: Canadian Institutes of Health Research (CIHR) through the Drug Safety and Effectiveness Network (DSEN)
[/no-bottom-margin]
Share Buttons [span][/span]
[ssba-buttons] [/sidebar] [sidebar-content]- Provided Health Canada with evidence on the safety of these agents for their decision-making
- ECG monitoring of chemotherapy patients administered with serotonin (5-HT3) receptor antagonists did not reveal clinically significant differences in arrhythmia between the medications at the examined time periods
Altmetrics:
Related Projects:
[/sidebar-content]Category : KS Projects
Date : 17 Sep 2020